INDIANAPOLIS (Inside INdiana Business) — The U.S. government is purchasing a minimum of 100,000 doses of a combination antibody therapy created by Indianapolis-based Eli Lilly and Co. (NYSE: LLY) for the treatment of mild to moderate COVID-19 patients.
Lilly says the purchase agreement of $210 million is for a cocktail of bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016).
The company says it recently received emergency use authorization for the treatment of recently diagnosed, mild to moderate COVID-19 in patients who are at high risk of progressing to severe cases and possible hospitalization.
The agreement gives the government the option to purchase an additional 1.1 million doses through November under the same terms and subject to medical need in the country.
“Every day, thousands of Americans are diagnosed with COVID-19, with many at high risk of…